SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia shares are under pressure amid the boards investigation into CEO Jensen Huang following reports of ties to a suspected Chinese spy, with traders also focused on allegations of China-bound chip sales and possible leadership or export-control fallout. The selloff has split the community between dip buyers who view the reaction as overdone and bears concerned about legal scrutiny and uncertainty around China exposure.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers shares are under pressure after a disappointing Q3 report, with weaker-than-expected profitability, compressed margins, a reduced outlook and a sequential subscriber decline outweighing strong revenue growth. Traders are split between concerns about execution and competition and hopes that international expansion, the Lilly partnership and the Peptides+ launch can revive growth.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,110,071. The last known price of Bitcoin is 74,895.40905656 USD and is down -0.28 over the last 24 hours. It is currently trading on 12776 active market(s) with $26,892,693,016.04 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Hotter-than-expected U.S. inflation strengthened expectations of further Fed rate hikes, adding pressure to Bitcoin and other risk assets; traders also cited leveraged liquidations as amplifying the crypto selloff. The community is split between bearish calls for more downside and buyers viewing the decline as an opportunity to accumulate.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsofts winding down of Oracle AI-compute rentals and reassessment of other data-center commitments has fueled concern that AI infrastructure spending is slowing, adding pressure to the stock. Traders debate whether this signals weaker AI demand or a shift toward Microsofts own capacity and better-fitting suppliers, with some viewing the pullback as optimization rather than retreat.

Zcash (ZEC) is a cryptocurrency . Users are able to generate ZEC through the process of mining. Zcash has a current supply of 16,957,873.22986632. The last known price of Zcash is 1,170.00468254 USD and is down -4.93 over the last 24 hours. It is currently trading on 669 active market(s) with $1,123,501,581.28 traded over the last 24 hours. More information can be found at https://z.cash/.

Zcash

Zcash is drawing attention after a sharp pullback from a major rally, with traders citing an unwind, profit-taking and broader crypto liquidations as possible factors rather than a confirmed single catalyst. The reaction is split between bearish calls for more downside and dip-buying bulls pointing to Zcashs privacy appeal and network upgrades.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.09792366 USD and is down -1.80 over the last 24 hours. It is currently trading on 1894 active market(s) with $2,759,095,442.76 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRP is under pressure amid a broader crypto selloff, with traders pointing to Bitcoins decline, leveraged liquidations and rate concerns. The community is split between buyers accumulating the dip and bearish traders warning of more downside, with some also questioning whether Ripples growth benefits the token.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Q3 results have sparked debate: traders are weighing strong revenue and backlog growth against a wider-than-expected loss and Neutrons first launch being pushed to 2027. Some see the growth and launch bookings as evidence of momentum, while others are concerned about profitability and execution delays.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IRENs sharp selloff is being linked to broader neocloud weakness and concerns about Microsoft-related buildout delays, debt, funding needs and dilution; some traders instead point to CPI and market-wide pressure. Bulls cite strong AI-cloud results and backlog as reasons to buy the dip, while bears question execution and financing risks.

Ethereum (ETH) is a cryptocurrency . Ethereum has a current supply of 122,203,846.69715353. The last known price of Ethereum is 2,121.02700944 USD and is down -0.91 over the last 24 hours. It is currently trading on 14303 active market(s) with $13,174,532,202.61 traded over the last 24 hours. More information can be found at https://www.ethereum.org/.

Ethereum

Ethereum is drawing attention amid a sharp crypto-wide selloff, with traders pointing to hot inflation data, renewed Fed rate-hike concerns and leveraged long liquidations as pressure on prices. The conversation is mostly bearish, though some traders see the decline as a buying opportunity and watch for support or a rebound.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

A hotter-than-expected CPI reading and rising Treasury yields and dollar are weighing on gold, prompting a sharp pullback in GLD as traders reassess the outlook for Fed policy. Bears expect more downside, while some traders call the move an overreaction and see a buying opportunity, with debate also focused on golds inconsistent safe-haven behavior.

statis crypto Watchlist

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Apogee Enterprises (APOG) Up 16.7% Since Last Earnings Report?

Apogee Enterprises (APOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

What Makes Apogee Enterprises (APOG) a Good Fit for 'Trend Investing'

Apogee Enterprises (APOG) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Is Apogee Enterprises (APOG) Outperforming Other Industrial Products Stocks This Year?

Here is how Apogee Enterprises (APOG) and Idex (IEX) have performed compared to their sector so far this year.

Zacks Industry Outlook Highlights O-I Glass, Inc. and Apogee Enterprises

O-I Glass and Apogee Enterprises could benefit from rising demand for sustainable glass packaging, energy-efficient windows and innovative construction products.

2 Glass Products Stocks to Watch in a Promising Industry

Solid end-market demand and focus on unveiling innovative products will aid the Zacks Glass Products industry's growth. This bodes well for stocks like OI and APOG.

IBRX Stock Rises Overnight: Jim Cramer Backs ImmunityBio As A ‘Very Good Spec’ Amid Biotech Takeover Wave

Equity

ImmunityBio expects November results from a 366-patient Anktiva trial and plans a fourth-quarter FDA filing.

Best Momentum Stock to Buy for October 19th

APOG, CNQ and EOG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 19, 2026.

Best Income Stocks to Buy for October 19th

VSNT, CNQ and APOG made it to the Zacks Rank #1 (Strong Buy) income stocks list on October 19, 2026.

New Strong Buy Stocks for October 19th

ACIC, APOG, EOG, CRCL and ASAIY have been added to the Zacks Rank #1 (Strong Buy) List on October 19, 2026.

Are Industrial Products Stocks Lagging  Apogee Enterprises (APOG) This Year?

Here is how Apogee Enterprises (APOG) and Ball (BALL) have performed compared to their sector so far this year.

Apogee Enterprises, Inc. engages in the design and development of architectural products and services. It also provides architectural glass, aluminum framing systems, and installation services for buildings, as well as value-added glazing products for custom picture framing. The firm operates through the following segments: Architectural Metals, Architectural Glass, Architectural Services, and Performance Surfaces. The Architectural Metals segment designs, engineers, fabricates and finishes aluminum window, curtainwall, storefront and entrance systems comprising the exterior of buildings. The Architectural Glass segment fabricates coated glass used in custom window and wall systems. The Architectural Services segment integrates technical services, project management, and field installation services to design, engineer, fabricate, and install building glass and curtainwall systems. The Performance Surfaces segment develops and manufactures coated materials for a variety of applications. The company was founded in 1949 and is headquartered in Minneapolis, MN.

Apogee Enterprises Inc.

Neutral Sentiment

<ul class="summary-bullets"><li>The FDA expanded approval of Anktiva plus BCG to include papillary-only bladder tumors earlier this month.</li><li>A separate study reported a 71% complete response rate, with some responses lasting more than 53 months.</li><li>Recent sector deals include AbbVie’s $10.9 billion acquisition of Apogee Therapeutics and Viatris’s $1.65 billion agreement to buy Pacira BioSciences.&nbsp;</li></ul>ImmunityBio (IBRX) shares rose nearly 1% overnight heading into Tuesday after CNBC host Jim Cramer called it a “very good spec,” citing a wave of biotech acquisitions as the company advances plans to expand the use of its flagship drug, Anktiva, in bladder cancer.<a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> closed Monday down about 5% at $7.81, logging its fourth straight session in the red.&nbsp;&nbsp;<h2 class="st-heading-2">Biotech Deal Wave Fuels Cramer’s IBRX Call</h2>Cramer backed ImmunityBio as a speculative bet during Monday’s&nbsp;Mad Money Lightning Round, saying it could pay off even when index funds disappoint.“I don’t mind you taking a position in that, because that’s one of those that you could look back and say, you know what? I was in my index funds, they didn’t really do well, but man, did I clean up on a very good spec,” he said.He pointed to biotech takeovers as part of the appeal. “The biotechs are being taken over like mad, you want to be in one,” Cramer said. The call echoes his June stance, when he encouraged investors to limit speculation to one holding. “Let Immunitybio be your speculation,” he said&nbsp;then.Cramer’s takeover pitch follows a string of recent big drugmaker deals. Earlier this month, Viatris agreed to buy Pacira BioSciences for $1.65 billion, with closing expected by year-end. AbbVie completed its $10.9 billion acquisition of Apogee Therapeutics in September, while Eli Lilly agreed in August to acquire Merida Biosciences for up to $2.875 billion, including milestone payments.&nbsp;<h2 class="st-heading-2">IBRX Eyes Earlier Treatment With November Readout</h2>Cramer’s backing comes ahead of a November readout that could help ImmunityBio bring Anktiva to patients earlier in bladder cancer treatment. Last week, the company finished checking data from a 366-patient trial comparing Anktiva plus BCG with BCG alone in non-muscle invasive bladder cancer, clearing the way for the final analysis.The study focuses on patients receiving BCG-based treatment for the first time. Anktiva’s current approval covers patients whose disease has not responded to BCG.ImmunityBio also plans to submit an application to expand FDA approval in the fourth quarter. The analysis will assess how many patients achieve a complete response, meaning no detectable cancer under the study’s criteria, and how long those responses last.&nbsp;<h2 class="st-heading-2">Anktiva Gains Broader Approval And Fresh Long-Term Data</h2>Earlier this month, the FDA expanded ANKTIVA plus BCG’s approval to include patients with BCG-unresponsive non-muscle invasive bladder cancer with papillary-only tumors. That builds on its 2024 approval for disease with carcinoma in situ, with or without papillary tumors.The company also released long-term results this month from a Phase 2/3 study of 100 patients whose cancer had not responded to BCG. It reported a 71% complete response rate, with some responses lasting more than 53 months. Among responders, three-year survival without bladder-removal surgery was 84%.&nbsp;<h2 class="st-heading-2">How Do Retail Traders Feel About IBRX?</h2>On Stocktwits, retail sentiment slipped to ‘bearish’ from ‘bullish’ levels a week ago amid a 274% surge in 24-hour message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/ibrx_ss_b5882aaeea.png" alt="ibrx ss.png" width="638" height="352"><figcaption>IBRX sentiment and message volume as of October 27 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/Oceanviews/message/667415901">said</a>, “$IBRX cramer has never been so bullish on Ibrx as he was yesterday. Last time the stock traded in the 7's , cramer was bullish on Ibrx and started the rally to 10+ “<stembedurl>https://stocktwits.com/Oceanviews/message/667415901</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Patient_Monk/message/667413904">said</a>, “$IBRX I buy the dips and exhaust my powder, it goes so much lower and I cannot buy more.”<stembedurl>https://stocktwits.com/Patient_Monk/message/667413904</stembedurl>IBRX stock has surged 294% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/spcx-stock-analyst-upside-without-tesla-merger-even-if-revenue-misses-goals/cZUIUX2RBzF">SPCX Stock Up Nearly 10% Since IPO — Analyst Sees 82% Upside Without Tesla Merger, Even If Revenue Misses Lofty Goals&nbsp;</a>

In this photo illustration, the ImmunityBio logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Abbvie Inc

ImmunityBio Inc

Viatris Inc

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	$0.81	--	--	N/A
Q2 '26	$0.59	$1.17	98.31%	BEAT
Q1 '26	$0.45	$0.57	27.61%	BEAT
Q4 '25	$0.88	$0.92	4.94%	BEAT
Q3 '25	$1.02	$1.02	0.25%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

APOG Earnings

Upcoming Earnings: Q3 '26

Historical Earnings